Protracted febrile myalgia syndrome (PFMS) is a rare, dramatic manifestation of familial Mediterranean fever (FMF) and is considered to be either an extension of the inflammation associated with FMF or a rare type of vasculitis associated with the same disease which is characterized by severe paralyzing myalgia of the upper and lower extremities, high fever, normal creatine kinase, and elevated acute phase reactants. A striking feature of PFMS is that the symptoms respond very effectively to corticosteroids, and without this treatment, the symptoms last for four-six weeks. Patients are diagnosed with PFMS on the basis of the presence of these clinical and laboratory characteristics. In addition, it is known to be associated with Mediterranean Fever (MEFV) gene mutations; however, its environmental triggering mechanisms are unknown.

In this report, we present a patient who developed PFMS after long-duration travel and hyperthermal (≥40 °C) balneotherapy. To the best of our knowledge, this is the first case report which proposes a relationship between PFMS and balneotherapy.
travel and hyperthermal (>40 °C) balneotherapy, with the goal of drawing attention to the possible environmental triggers of this syndrome. To our knowledge, this is the first article that proposes a possible relationship between PFMS and balneotherapy.

**CASE REPORT**

A 33-year-old male patient was admitted to the emergency department of our hospital complaining of generalized, continuous, severe paralyzing myalgia, abdominal pain, and high fever (38.5-39.5 °C) that had began four days earlier. Due to the severe myalgia, he was unable to walk without help. A physical examination revealed diffuse muscular and abdominal tenderness, but there were no skin lesions on the patient nor was there lymph node enlargement. The chest X-ray and abdominal ultrasonography results were normal. The patient was hospitalized for observation in the general surgical ward, and conservative treatment that included intravenous antibiotics and analgesics was initiated. Laboratory analyses revealed leukocytosis (13.940/mm³) with neutrophil predominance (82.2%) and thrombocytosis (460.000/mm³) along with normal eosinophil, rheumatoid factor (RF), and anti-streptolysin O (ASO) titer levels. The results for routine biochemical blood tests, including an evaluation of creatine kinase (CK) and transaminases, and urine tests were normal, and stool test results for parasites and occult blood were negative as well. The C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and fibrinogen levels were 51.94 mg/L, 36 mm/h, and 508 mg/dL respectively, and all were elevated. Furthermore, the serology for brucellosis, salmonellosis, hepatitis B virus, and hepatitis C virus was negative, and blood and throat cultures for the patient were sterile. On the fourth day of hospitalization, because of the ongoing paralyzing myalgia and high fever, the patient was referred to a physiatrist due to the suspicion of FMF. When the patient was questioned, he stated that his symptoms had begun after long-duration travel and hyperthermal balneotherapy, and his previous medical history revealed typical FMF attacks, which can cause recurrent high fever and abdominal pain with spontaneous remission. Thus, the patient was diagnosed with FMF as well as PFMS, and methylprednisolone (1 mg/kg/day) treatment was started. His symptoms then disappeared, and the acute-phase reactant levels declined rapidly, supporting the diagnosis of PFMS. Colchicine (1 mg/day) was added to the treatment, and the patient was gradually weaned from the methylprednisolone. A mutational analysis of the MEFV gene demonstrated heterozygous V726A mutation in exon 10, which confirmed the diagnoses of PFMS and FMF; hence, the colchicine treatment was continued. During the six-month follow-up period, the patient experienced none of previously described clinical episodes of FMF nor any new attacks of PFMS. In addition, the acute-phase reactant levels remained within the normal range.

**DISCUSSION**

Protracted febrile myalgia syndrome is an extension of the inflammation associated with FMF or a rare form of vasculitis that is an FMF-specific manifestation characterized by severe paralyzing myalgia and high fever with normal CK levels but elevated CRP and ESR.[1,2] Another noteworthy feature of PFMS is that the signs and symptoms dramatically respond to corticosteroids.[1-3] These findings contribute significantly to the diagnosis of this syndrome, but a genetic analysis is still required to confirm the diagnosis. In addition to the clinical and laboratory features, our patient fulfilled other criteria with the presence of the MEFV mutation and his dramatic response to the corticosteroid treatment, both of which led to the diagnosis of PFMS and FMF.

Because PFMS may recur even with the colchicine prophylaxis,[3] it is important to recognize the environmental triggers that cause this syndrome in order to prevent its occurrence. It is known that various MEFV mutations are associated with PFMS, but the specific mechanisms that precipitate this syndrome are unclear. Unlike previous reports in which most patients had a homozygous M694V mutation,[4,5] our patient was heterozygous for the V726A mutation. Additionally, our patient was also different from some of the previously published cases[3,6] involving PFMS in terms of the possible environmental triggers. While long-duration travel and hyperthermal balneotherapy are the most likely causes of PFMS in our patient, diabetic ketoacidosis[6] and streptococcal infections[3] have been suggested in other cases. It is also possible that some factors might result in a change in the proinflammatory cytokine level, and these could also bring about the attacks.[7]
In a study by Karadağ et al. [8] that investigated the potential causes of FMF attacks, they found a relationship between the MEFV mutations and the triggering factors in which the M694V allele was associated with starvation while the V726A allele was associated with long-duration travel.[8] Similarly, our patient had traveled for a long period of time, and the V726A mutation was identified in his MEFV gene. However, in our review of the literature, we could not find any study that specifically focused on the potential triggering mechanisms of PFMS.

In our patient, the syndrome began about 16 hours after hyperthermal balneotherapy; hence, it is logical to conclude that this type of therapy might be a risk factor for PFMS. Because healthy heterozygotes for MEFV mutations have higher than normal acute-phase reactant levels, and many FMF patients continue to have subclinical inflammation during attack-free periods.[9] Thus, the effect of the hyperthermal balneotherapy on our patient might have been increased due to his existing chronic inflammation. Furthermore, PFMS had already been considered to be an extension of FMF inflammation by Bircan and Usluer [2].

Familial Mediterranean fever attacks that coexist with thermal crisis, a side effect of balneotherapy, should be considered as a differential diagnosis. The clinical picture associated with thermal crisis can include local or general symptoms such as anorexia, sleep disturbances, irritability, hot and cold intolerance, changes in libido, limb paresthesia, muscle tone changes, tremors, and dermatographism.[10] However, none of these symptoms was evident in our patient.

In conclusion, depending on the different MEFV mutations, the triggering factors may be different in FMF. As was the case with our patient, long-duration travel and hyperthermal balneotherapy are possible environmental triggers for PFMS patients with the V726A mutation.

Declaration of conflicting interests
The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Funding
The authors received no financial support for the research and/or authorship of this article.

REFERENCES